GlassScriptPhysician profile
Craig J Denny
NPI 1720071319
$10,231.45
in general payments reported to CMS, 2019-2025
27 companies · $2,008 in 2025
The $2,008 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $1,179 · 2021: $1,048 · 2022: $1,479 · 2023: $1,523 · 2024: $2,029 · 2025: $2,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,475 · Education: $85.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,475.09 |
| Education | $85.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,936.18 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,271.93 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,269.99 | 2021-2025 | Vraylar |
| Allergan, INC. | $940.29 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $695.41 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $640.20 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $558.19 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $525.76 | 2022-2025 | Auvelity |
| Alkermes, INC. | $410.93 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $395.29 | 2020-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $323.38 | 2024-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $283.95 | 2019-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $238.56 | 2019-2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $141.19 | 2019-2025 | Ingrezza |
| Merck Sharp & Dohme LLC | $138.12 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $66.95 | 2024-2025 | Cobenfy |
| Eisai INC. | $65.93 | 2020-2021 | |
| Corium, LLC | $55.42 | 2022-2024 | Azstarys |
| Collegium Pharmaceutical, INC. | $53.22 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $46.16 | 2019-2025 | Trintellix |
| Shire North American Group INC | $40.95 | 2019 | |
| Indivior INC. | $35.37 | 2022-2024 | Perseris |
| Arbor Pharmaceuticals, INC. | $28.62 | 2019 | |
| Janssen Scientific Affairs, LLC | $27.31 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.02 | 2024 | Quviviq |
| Tris Pharma INC | $13.86 | 2023 | Dyanavel Xr |
| Almatica Pharma LLC | $13.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Denny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.